ATC Group: J01FF02 Lincomycin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01FF02 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01F Macrolides, lincosamides and streptogramins
4 J01FF Lincosamides
5 J01FF02 Lincomycin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1.8 g
PAREN - Parenteral 1.8 g

Active ingredients in J01FF02

Active Ingredient Description
Lincomycin

Lincomycin is an antibiotic produced by fermentation of Streptomyces lincolnensis. Lincomycin inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome.

Related product monographs

Title Information Source Document Type  
LINCOCIN Solution for injection Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Cyprus (CY)

Ecuador (EC)

Hong Kong (HK)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Poland (PL)

Singapore (SG)

Spain (ES)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.